Compass treatments provide data for CTX-8371, a
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a biotechnology company focused on clinical-stage oncology and developing antibody-based therapies to treat many human diseases, today reports new preclinical data on CTX-8371, a next-generation bispecific checkpoint inhibitor. which simultaneously targets PD-1 and PD-L1 and presents a unique MOA that includes PD-1 cell …